-+ 0.00%
-+ 0.00%
-+ 0.00%

Liquidia Q3 2026 net loss widens year over year to $236.3 million

PUBT·11/10/2026 11:31:15
Listen to the news
Liquidia Q3 2026 net loss widens year over year to $236.3 million
  • Liquidia’s third-quarter 2026 net loss widened year over year to $236.3 million, including a $389.7 million litigation settlement charge.
  • YUTREPIA net product sales rose to $222.7 million, up 31% from the second quarter of 2026.
  • Cash and cash equivalents more than doubled from December 31, 2025, to $396.1 million at September 30, 2026, before settlement payments.
  • A global settlement with United Therapeutics requires $380.7 million in net payments during 2026–2027 while preserving uninterrupted patient access to YUTREPIA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100630PRIMZONEFULLFEED9874084) on November 10, 2026, and is solely responsible for the information contained therein.